Skip to main content

Table 2 Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo (ASA + placebo).

From: Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy

 

Ischemic Events

Bleeding Events

Trial

(observation period)

clop + ASA (%)

ASA + placebo (%)

p

NNT

clop + ASA

(%)

ASA + placebo

(%)

p

NNH

Cure [36]

(1 year)

9.3

11.4

<0.001

47.6

major 3.7

minor 5.1

total 8.5

major 2.7

minor 2.4

total 5.0

<0.001

<0.001

<0.001

100

37

28.6

Credo [38]

(1 years)

8.5

11.2

0.02

37.0

severe 8.8

minor 5.3

severe 6.7

minor 5.6

0.07

0.92

250

Charisma [3]

(2.5 years)

6.8

7.3

0.22

200

severe 1.7

moderate 2.1

moderate + severe 3.8

severe1.3

moderate 1.3

moderate + severe 2.6

0.09

<0.001

<0.001

250

125

83.3

  1. Comparison of ischemic risk prevention and bleeding with clopidogrel plus aspirin (clop + ASA) versus aspirin plus placebo (ASA + placebo). Aspirin plus clopidogrel increased the incidence of bleeding events compared with aspirin plus placebo. Comparing the primary endpoint reduction with the two treatments, it appears that increased frequency of bleeding can limit the benefits of combined therapy.
  2. NNT: Number Needed to Treat
  3. NNH: Number Needed to Harm